Table S1 presents the characteristic features of the study population divided based on the median exo-CD40 levels. We found that patients with a lower expression of exo-CD40 had a significantly favorable overall survival rate in comparison to the higher exo-CD40 expression (Figure 2D). As age is one of the important factors during pancreatic cancer, we analyzed whether age of the PDAC, pancreatitis or clinical control patients played a role in the expression of exo-CD40. We did not see any alterations (Figure S4E–G). This evidence concerns the gene CD40 and familial pancreatic carcinoma.